📄 Publications
An Objective Assessment of Effect of Stimulants on Attention in Individuals With ADHD
Currently, assessing ADHD treatment response to stimulants relies on rating scales and subjective questionnaires. Such tools fall short of objective, quantifiable measurement — especially in natural settings.
Read in Journal of Attention Disorders →
Objective Measurement of Lisdexamfetamine's Effects on Reading Patterns in ADHD: A Case Report Using Eye-Tracking
This case report investigates the temporal dynamics of lisdexamfetamine (Vyvanse) in an adult patient with ADHD through novel eye-tracking methodology using iFocus.
Read at Juniper Publishing →📰 Articles
Eye-tracking assessments could be the future of ADHD treatment evaluation
A recent study in the Journal of Attention Disorders details the development of a novel method to objectively measure the effects of stimulant medication on individuals with ADHD.
Read on PsyPost →
Exploring Tech-Based Symptom Tracking for ADHD
Benjamin and Sarah Cheyette, M.D. discuss exciting new developments that could help track symptom severity in ADHD patients.
Read on Psychology Today →
How Eye Movement Can Gauge ADHD Medication Efficacy
"I wanted a better way to tell if my child's ADHD medication was working. So, I invented a tool that does that." — Adi Diner, CEO of iFocus Health.
Read on ADDitude Magazine →
Changing the Game: Redefining Direct-to-Consumer Purchasing Models in Mental Health Markets
Insights on the connection between the aesthetic and mental health markets, and the "White Coat Effect" in healthcare marketing from advisor Yulie Klerman.
Read on LinkedIn →
The Intersection of AI and ADHD
Like any new technology, AI is not good or bad. In some aspects, it is uniquely qualified to solve some issues related to ADHD. In others, it carries risks that will affect people with ADHD more than neurotypicals.
Read on Medium →
People Behind Healthcare Innovation: Interview with Adi Diner
A conversation with Adi Diner, Co-Founder and CEO of iFocus Health — a company that collects data to measure ADHD treatment efficacy.
Read on LinkedIn →🎓 Lectures
It's All in the Eye – Finding the Right Measure and Data for an ADHD Treatment Biomarker
Lecture at AI Week, Tel Aviv University. Discusses iFocus's AI algorithms that analyze eye-tracking data to identify reliable biomarkers for ADHD treatment.
Watch on YouTube →🎙️ Podcasts
Ep435 – Adi Diner | Co-Founder, CEO, iFocus
Adi Diner, physicist and CEO, discusses how 1 in 10 children and adults have ADHD, and how iFocus is changing the way ADHD is treated through objective treatment efficacy measures.
Listen on Spotify →
Catching Up With ADHD Tech Pioneer Adi Diner of iFocus Health
Adi gives an update on the groundbreaking tool she's been working on and explains how you can use this free tool to check whether your medicine is working.
Watch on YouTube →
S8 Bonus: Einat Sitbon, iFocus Health – Code Story by Noah Labhart
The creation story of iFocus Health — told by CTO and Co-Founder Einat Sitbon, a computational biologist who set out to solve a problem her nephew's ADHD diagnosis brought to light.
Listen on Spotify →
Ep78 – New ADHD Care: Adi Diner Talks About iFocus
Adi Diner, diagnosed with ADHD as an adult, launched iFocus to help children and adults determine if their ADHD treatment is actually working.
Watch on YouTube →
Dr. Ned Hallowell – iFocus Measures How Well Your ADHD Treatments Work
Dr. Hallowell interviews Adi Diner about iFocus — a program using eye-tracking technology and proprietary AI to enable doctors to create optimal treatment plans.
Watch on YouTube →
LTP022 Dr. Adi Diner – Changing The Standard of Care for People with ADHD
Adi discusses how iFocus uses only a webcam and Chrome extension to do eye-tracking, recording data that doctors use to determine whether a patient is improving.
Listen on Spotify →
760 – Adi Diner (iFocus Health): Building The First Real ADHD Monitoring System
iFocus is using eye-tracking technology combined with a proprietary AI algorithm to create the first real ADHD monitoring system — discussed in this founder conversation.
Listen on Spotify →